141 related articles for article (PubMed ID: 11125034)
21. Evidence that wild-type p53 in neuroblastoma cells is in a conformation refractory to integration into the transcriptional complex.
Wolff A; Technau A; Ihling C; Technau-Ihling K; Erber R; Bosch FX; Brandner G
Oncogene; 2001 Mar; 20(11):1307-17. PubMed ID: 11313875
[TBL] [Abstract][Full Text] [Related]
22. E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines.
Kitagawa M; Aonuma M; Lee SH; Fukutake S; McCormick F
Oncogene; 2008 Sep; 27(40):5303-14. PubMed ID: 18521084
[TBL] [Abstract][Full Text] [Related]
23. HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation.
Zhou BP; Liao Y; Xia W; Zou Y; Spohn B; Hung MC
Nat Cell Biol; 2001 Nov; 3(11):973-82. PubMed ID: 11715018
[TBL] [Abstract][Full Text] [Related]
24. The p53 pathway and its inactivation in neuroblastoma.
Tweddle DA; Pearson AD; Haber M; Norris MD; Xue C; Flemming C; Lunec J
Cancer Lett; 2003 Jul; 197(1-2):93-8. PubMed ID: 12880966
[TBL] [Abstract][Full Text] [Related]
25. Retinoic acid confers resistance to p53-dependent apoptosis in SH-SY5Y neuroblastoma cells by modulating nuclear import of p53.
Ronca F; Yee KS; Yu VC
J Biol Chem; 1999 Jun; 274(25):18128-34. PubMed ID: 10364268
[TBL] [Abstract][Full Text] [Related]
26. Cyclooxygenase inhibitors modulate the p53/HDM2 pathway and enhance chemotherapy-induced apoptosis in neuroblastoma.
Lau L; Hansford LM; Cheng LS; Hang M; Baruchel S; Kaplan DR; Irwin MS
Oncogene; 2007 Mar; 26(13):1920-31. PubMed ID: 16983334
[TBL] [Abstract][Full Text] [Related]
27. Additive effect of adenovirus-mediated E2F-1 gene transfer and topoisomerase II inhibitors on apoptosis in human osteosarcoma cells.
Yang HL; Dong YB; Elliott MJ; Wong SL; McMasters KM
Cancer Gene Ther; 2001 Apr; 8(4):241-51. PubMed ID: 11393276
[TBL] [Abstract][Full Text] [Related]
28. Apoptosis of tumoral and nontumoral lymphoid cells is induced by both mdm2 and p53 antisense oligodeoxynucleotides.
Capoulade C; Mir LM; Carlier K; Lécluse Y; Tétaud C; Mishal Z; Wiels J
Blood; 2001 Feb; 97(4):1043-9. PubMed ID: 11159535
[TBL] [Abstract][Full Text] [Related]
29. Cytoplasmically "sequestered" wild type p53 protein is resistant to Mdm2-mediated degradation.
Zaika A; Marchenko N; Moll UM
J Biol Chem; 1999 Sep; 274(39):27474-80. PubMed ID: 10488081
[TBL] [Abstract][Full Text] [Related]
30. Retinoic acid-induced apoptosis of the CHP134 neuroblastoma cell line is associated with nuclear accumulation of p53 and is rescued by the GDNF/Ret signal.
Takada N; Isogai E; Kawamoto T; Nakanishi H; Todo S; Nakagawara A
Med Pediatr Oncol; 2001 Jan; 36(1):122-6. PubMed ID: 11464863
[TBL] [Abstract][Full Text] [Related]
31. A transforming p53 mutant, which binds DNA, transactivates and induces apoptosis reveals a nuclear:cytoplasmic shuttling defect.
Crook T; Parker GA; Rozycka M; Crossland S; Allday MJ
Oncogene; 1998 Mar; 16(11):1429-41. PubMed ID: 9525742
[TBL] [Abstract][Full Text] [Related]
32. HMG-CoA reductase inhibitors, statins, induce phosphorylation of Mdm2 and attenuate the p53 response to DNA damage.
Pääjärvi G; Roudier E; Crisby M; Högberg J; Stenius U
FASEB J; 2005 Mar; 19(3):476-8. PubMed ID: 15625077
[TBL] [Abstract][Full Text] [Related]
33. Synergistic activation of p53 by inhibition of MDM2 expression and DNA damage.
Chen L; Agrawal S; Zhou W; Zhang R; Chen J
Proc Natl Acad Sci U S A; 1998 Jan; 95(1):195-200. PubMed ID: 9419352
[TBL] [Abstract][Full Text] [Related]
34. Functional role of Mdm2 phosphorylation by ATR in attenuation of p53 nuclear export.
Shinozaki T; Nota A; Taya Y; Okamoto K
Oncogene; 2003 Dec; 22(55):8870-80. PubMed ID: 14654783
[TBL] [Abstract][Full Text] [Related]
35. Nuclear accumulation of p53 following inhibition of transcription is not due to diminished levels of MDM2.
O'Hagan HM; Ljungman M
Oncogene; 2004 Jul; 23(32):5505-12. PubMed ID: 15094782
[TBL] [Abstract][Full Text] [Related]
36. Oncoprotein expression of E6 and E7 does not prevent 5-fluorouracil (5FU) mediated G1/S arrest and apoptosis in 5FU resistant carcinoma cell lines.
Didelot C; Mirjolet JF; Barberi-Heyob M; Ramacci C; Teiten MH; Merlin JL
Int J Oncol; 2003 Jul; 23(1):81-7. PubMed ID: 12792779
[TBL] [Abstract][Full Text] [Related]
37. ZBP-89 promotes growth arrest through stabilization of p53.
Bai L; Merchant JL
Mol Cell Biol; 2001 Jul; 21(14):4670-83. PubMed ID: 11416144
[TBL] [Abstract][Full Text] [Related]
38. Mdm2 inhibition of p53 induces E2F1 transactivation via p21.
Wunderlich M; Berberich SJ
Oncogene; 2002 Jun; 21(28):4414-21. PubMed ID: 12080472
[TBL] [Abstract][Full Text] [Related]
39. Drug-resistant breast cancer cells frequently retain expression of a functional wild-type p53 protein.
Gudas JM; Nguyen H; Li T; Sadzewicz L; Robey R; Wosikowski K; Cowan KH
Carcinogenesis; 1996 Jul; 17(7):1417-27. PubMed ID: 8706243
[TBL] [Abstract][Full Text] [Related]
40. Regulation of p53 by hypoxia: dissociation of transcriptional repression and apoptosis from p53-dependent transactivation.
Koumenis C; Alarcon R; Hammond E; Sutphin P; Hoffman W; Murphy M; Derr J; Taya Y; Lowe SW; Kastan M; Giaccia A
Mol Cell Biol; 2001 Feb; 21(4):1297-310. PubMed ID: 11158315
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
